- Home
- BIDU vs INSM Comparison
BIDU vs INSM Comparison
Compare BIDU & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIDU
- INSM
- Stock Information
- Founded
- BIDU 2000
- INSM 1988
- Country
- BIDU China
- INSM United States
- Employees
- BIDU N/A
- INSM N/A
- Industry
- BIDU Computer Software: Programming Data Processing
- INSM Biotechnology: Pharmaceutical Preparations
- Sector
- BIDU Technology
- INSM Health Care
- Exchange
- BIDU Nasdaq
- INSM Nasdaq
- Market Cap
- BIDU 30.9B
- INSM 29.0B
- IPO Year
- BIDU 2005
- INSM 2000
- Fundamental
- Price
- BIDU $138.77
- INSM $161.17
- Analyst Decision
- BIDU Strong Buy
- INSM Strong Buy
- Analyst Count
- BIDU 9
- INSM 19
- Target Price
- BIDU $123.67
- INSM $152.71
- AVG Volume (30 Days)
- BIDU 7.6M
- INSM 2.2M
- Earning Date
- BIDU 11-20-2025
- INSM 10-30-2025
- Dividend Yield
- BIDU N/A
- INSM N/A
- EPS Growth
- BIDU 41.81
- INSM N/A
- EPS
- BIDU 10.88
- INSM N/A
- Revenue
- BIDU $18,544,068,789.00
- INSM $398,105,000.00
- Revenue This Year
- BIDU N/A
- INSM $32.44
- Revenue Next Year
- BIDU $5.07
- INSM $123.99
- P/E Ratio
- BIDU $12.77
- INSM N/A
- Revenue Growth
- BIDU N/A
- INSM 21.15
- 52 Week Low
- BIDU $74.71
- INSM $60.40
- 52 Week High
- BIDU $149.51
- INSM $162.44
- Technical
- Relative Strength Index (RSI)
- BIDU 66.03
- INSM 79.92
- Support Level
- BIDU $130.03
- INSM $136.62
- Resistance Level
- BIDU $149.51
- INSM $148.22
- Average True Range (ATR)
- BIDU 5.59
- INSM 4.38
- MACD
- BIDU 0.02
- INSM 0.56
- Stochastic Oscillator
- BIDU 58.35
- INSM 98.49
About BIDU Baidu Inc. ADS
Baidu is the largest internet search engine in China with over 50% share of the search engine market in 2024 per web analytics firm, Statcounter. The firm generated 72% of core revenue from online marketing services from its search engine in 2023. Outside its search engine, Baidu is a technology-driven company and its other major growth initiatives are artificial intelligence cloud, video streaming services, voice recognition technology, and autonomous driving.
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.